| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2814 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 |
| filingDate |
2021-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e346c7d2f5798b3908adc86f8752137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4559c7ca4c3b8670848c935060d99d3 |
| publicationDate |
2021-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021208142-A1 |
| titleOfInvention |
Method for detection and analysis of cerebrospinal fluid associated ube3a |
| abstract |
A method and kit for diagnosing Angelman Syndrome by detecting and analyzing ubiquitination of the UBE3A protein in cerebrospinal fluid is presented. CSF is collected from a patient and incubated with a substrate, such as S5a, and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and compared to a control sample for biochemical diagnosis of Angelman Syndrome. A method of determining the efficacy of a treatment is also presented in which CSF is collected from the patient both prior to and after treatment and incubated with a substrate and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and an increase in ubiquitination in the sample obtained after treatment as compared to the reference sample collected prior to treatment indicates efficacy of the treatment. |
| priorityDate |
2019-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |